Regeneron in Express Scripts’ Sights for Price War

After igniting a price war over hepatitis C medicine that has roiled the pharmaceutical industry, Express Scripts Holding Co. is looking to reap savings from expensive new treatments for cancer and high cholesterol.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.